References | n | Onset of PA | Indication for LT | Age at LT (years) | Graft type | Follow-up (months) | Post-LT PA-related complications | Post-LT transplant-related complications | Graft survival | Patient survival |
---|---|---|---|---|---|---|---|---|---|---|
Kayler et al. [34] | 1 | Early | n/a | 3 | Deceased | 0.3 | No | N/A | 0/1 | 0/1 |
Yorifuji et al. [33] | 3 | Early (n = 3) | PMC (n = 3) | 2.2 (1.2–5.1) | Living (n = 3) | 2.5 (1.8–4.9) | MD (n = 1) | N/A | 3/3 | 3/3 |
Manzoni et al. [32] | 1 | Early | PMC | 0.7 | Deceased | 0.8 | No | N/A | 1/1 | 1/1 |
Romano et al. [31] | 1 | Late | CM | 6.5 | Deceased | 0.5 | No | N/A | 1/1 | 1/1 |
Amelook et al. [30] | 1 | Late | CM | 16 | Deceased |  > 1 | No | N/A | 1/1 | 1/1 |
Kasahara et al. [29] | 3 | Early (n = 2) Late (n = 1) | PMC (n = 2) CM (n = 1) | 2 (0.6–2.2) | Living (n = 3) | 1.7 (1.4–3.4) | No | CMV (n = 2) | 3/3 | 3/3 |
Ryu et al. [28] | 1 | Early | PMC | 1.8 | Living | 0.01 | MD (n = 1) | HVO | 0/1 | 0/1 |
Arrizza et al. [27] | 1 | Late | CM | 22 | Deceased | 11 | No | N/A | 1/1 | 1/1 |
Charbit-Henrion et al. [15] | 12 | Early (n = 12) | PMC (n = 8)a CM (n = 3)a Preventative (n = 2) | 3.2 (1.1–9.0) | Deceased (n = 12) | 0.39 (0.01–21) | No | BS (n = 1), HAT (n = 4), Primary nonfunction (n = 13), PTLD (n = 2) | 5/17 | 5/12 |
Honda et al. [26] | 1 | Early | PMC | 4.0 | Living | 0.13 | No | AMR | 0/1 | 0/1 |
Silva et al. [25] | 2 | Early (n = 1) Late (n = 1) | CM (n = 2) | 12.5 and 5.5 | Deceased (n = 2) | 4 and 5 | No | N/A | 2/2 | 2/2 |
Critelli et al. [23] | 2 | Early | CM (n = 1) preventative (n = 1) | 8.7 and 1.2 | Deceased (n = 2) | 2.5 and 1.7 | No | ACR (n = 2), CMV (n = 1), HAT (n = 1) | 2/2 | 2/2 |
Moguilevitch et al. [24] | 1 | Early | PMC | 4.0 | Deceased | 2 | No | N/A | 1/1 | 1/1 |
Quintero et al. [14] | 6 | Early (n = 3) Late (n = 3) | PMC (n = 4) Preventative (n = 2) | 5.2 (1.3–7.5) | Living (n = 3) Deceased (n = 3) | 1.5 (0.5–4.0) | No | HAT (n = 2) | 6/6 | 6/6 |
Celik et al. [21] | 1 | Early | PMC | 11.8 | Living (unrelated) | 2.1 | No | HAT (n = 1) | 1/1 | 1/1 |
Chu et al. [10] | 2 | n/a | n/a | n/a | n/a | n/a | n/a | N/A | 2/2 | 2/2 |
Pillai et al. [22] | 8 | Early | PMC (n = 8) | 2.0 (0.4–9.4) | Deceased (n = 8) | 5.4 (1.3–17.1) | No | ACR (n = 2), Chronic rejection (n = 1), HAT (n = 1), IVC stenosis (n = 1), Portal vein stenosis (n = 1) | 8/9 | 8/8 |
Shanmugam et al. [20] | 5 | Early (n = 1) late (n = 1) n/a (n = 3) | PMC (n = 3) CM (n = 1) preventative (n = 1) | 2.8 (0.7–4.6) | Living (n = 5) | 2.8 (1.6–4.2) | MD (n = 1) | HAT (n = 1) | 5/5 | 5/5 |
Curnock et al. [13] | 14 | Early (n = 12) late (n = 1) n/a (n = 1) | PMC (n = 10) preventative (n = 4) | 2.4 (0.8–7.1) | Living (n = 1) deceased (n = 13) | 4.8 (0.1–22.3) | MD (n = 5) CM (n = 4) | ACR (n = 6), CMV (n = 6), HAT (n = 1), LCR (n = 2), PTLD (n = 1) | 11/16 | 11/14 |
Tuchmann-Durand et al. [19] | 1 | Early | PMC and CM | 5 | Deceased (n = 1) | 0.02 | n/a | N/A | 1/1 | 1/1 |